Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The filing details a specific transaction on February 17, 2012, where Mrs. K. Slaoui, a connected person of Executive Director Dr. M. Slaoui, sold 216 ADSs at a price of $44.98 per ADS. This sale was executed to meet tax liabilities following the vesting of an award granted in 2009 under the GlaxoSmithKline Share Value Plan. Following the sale, 424 ADSs were retained.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: February 17, 2012.
- Price per ADS: $44.98.
- Shares Sold: 216 ADSs by Mrs. K. Slaoui.
- Purpose: Payment of tax liabilities on vested 2009 awards.
- Remaining Holdings: 424 ADSs retained by the connected person.